HNGE vs IOVA
Hinge Health, Inc. vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
HNGE
Hinge Health, Inc.
64
Buy
VS
IOVA
Iovance Biotherapeutics, Inc.
64
Buy
| Metric | HNGE | IOVA |
|---|
| AI Score |
64
|
64
|
| Price |
$86.36
|
$6.74
|
| P/E Ratio |
66.10×
|
-9.27×
|
| ROE |
-139.6%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
84.5%
|
116.3%
|
| Debt / Equity |
0.02×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
69.6
|
79.2
|
| Beta |
1.285
|
0.701
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for HNGE versus IOVA.
The committee scores are tied.
HNGE and IOVA both score 64/100.
HNGE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 9.7x prices in significant intangible value — Value
- ROE of only -138.7% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 28.9% signals elevated volatility — Risk
IOVA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical